Evercore Inc.
No enriched coverage for $EVR in the last 7 days.
No SEC Form 4 filings for $EVR in the last 30 days.
Intellia Therapeutics (NTLA) rose in premarket after Evercore ISI upgraded it to Outperform from Inline. Evercore cited updated results for Intellia’s nex-z rare-disease gene-editing therapy, which it is developing with Regeneron (REGN).
Evercore ISI downgraded The Trade Desk to “In Line” from “Outperform” and cut its price target to $13 from $27, according to the firm. The article also notes Susquehanna downgraded the stock to “Neutral” and set a $14 target from $34. These changes may affect near-term sentiment and valuation expectations.
Evercore ISI reiterated an Outperform rating and $365 price target on Apple after Apple expanded its multi-year partnership with Broadcom. The deal is expected to exceed $30 billion, produce 15+ billion U.S.-made chips, and includes $1.5 billion in Apple capex to expand Broadcom’s Colorado facility through 2031.
Recent EVR coverage spans financial news, technology and sector analysis.
Intellia Therapeutics (NTLA) rose in premarket after Evercore ISI upgraded it to Outperform from Inline. Evercore cited updated results for Intellia’s nex-z rare-disease gene-editing therapy, which it is developing with Regeneron (REGN).
Evercore ISI downgraded The Trade Desk to “In Line” from “Outperform” and cut its price target to $13 from $27, according to the firm. The article also notes Susquehanna downgraded the stock to “Neutral” and set a $14 target from $34. These changes may affect near-term sentiment and valuation expectations.
Evercore ISI reiterated an Outperform rating and $365 price target on Apple after Apple expanded its multi-year partnership with Broadcom. The deal is expected to exceed $30 billion, produce 15+ billion U.S.-made chips, and includes $1.5 billion in Apple capex to expand Broadcom’s Colorado facility through 2031.
Evercore ISI raised its Phillips 66 price target to $220 from $200, according to the note published Aug. 6, 2026. The article also mentions Raymond James adjusting its Phillips 66 target to $240 from $235. Phillips 66 shares were shown at about $204.04 at 12:11 pm.
Evercore ISI raised its price target for Charles River Laboratories International (NYSE:CRL) to $300 from $260 and kept an Outperform rating, citing a return to organic revenue growth in the first quarter and a DSA book-to-bill of 1.19x. The firm projects 21% adjusted operating income margins for FY2026 and values shares at 23x 2027 earnings.
alphai scores every news story that mentions EVR with an AI model for sentiment and relevance, and aggregates insider trades from Evercore Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Intellia Therapeutics (NTLA) rose in premarket after Evercore ISI upgraded it to Outperform from Inline. Evercore cited updated results for Intellia’s nex-z rare-disease gene-editing therapy, which it is developing with Regeneron (REGN).
1 min readEvercore ISI downgraded The Trade Desk to “In Line” from “Outperform” and cut its price target to $13 from $27, according to the firm. The article also notes Susquehanna downgraded the stock to “Neutral” and set a $14 target from $34. These changes may affect near-term sentiment and valuation expectations.
2 min readEvercore ISI reiterated an Outperform rating and $365 price target on Apple after Apple expanded its multi-year partnership with Broadcom. The deal is expected to exceed $30 billion, produce 15+ billion U.S.-made chips, and includes $1.5 billion in Apple capex to expand Broadcom’s Colorado facility through 2031.
6 min readEvercore ISI raised its Phillips 66 price target to $220 from $200, according to the note published Aug. 6, 2026. The article also mentions Raymond James adjusting its Phillips 66 target to $240 from $235. Phillips 66 shares were shown at about $204.04 at 12:11 pm.
1 min readEvercore ISI raised its price target for Charles River Laboratories International (NYSE:CRL) to $300 from $260 and kept an Outperform rating, citing a return to organic revenue growth in the first quarter and a DSA book-to-bill of 1.19x. The firm projects 21% adjusted operating income margins for FY2026 and values shares at 23x 2027 earnings.
2 min readEvercore ISI reiterated an Outperform rating and a $150 price target on Uber Technologies (UBER) after the stock fell about 7% intraday to $68.08, near its 52-week low. The firm said the move reflects expectations correction, citing 20% bookings and 30% EBITDA growth, and catalysts tied to robotaxi rollouts and deal integration into 2027.
3 min readEvercore ISI named Live Nation Entertainment (LYV) its top media pick, citing accelerating venue growth. It pointed to Live Nation’s Q2 2026 results: revenue up 9.4% to $7.67B and adjusted operating income up 2.3% to $817M, beating estimates. Evercore kept Outperform and raised its price target to $218.
3 min readEvercore ISI lowered its price target on VICI Properties to $31 from $32 and kept an “In Line” rating, according to the firm. The article references VICI’s recent trading around $26.54 after hours. The change matters for investors tracking analyst target revisions and sentiment toward the REIT.
1 min readEvercore ISI adjusted its price target on Amazon.com to $315.16 from $315 and kept an Outperform rating, according to the firm. The note cites its composite methodology based on valuation, EPS revisions, and visibility metrics.
1 min readEvercore ISI reiterated an Outperform rating and $245 price target on Booking Holdings (BKNG). It expects an in-line or lower Q2 for the online travel company ahead of earnings on Aug. 4. Evercore cites achievable bookings, revenue, and room nights, with risks from Middle East impacts and FX. Street estimates for FY2026 are $203.7B bookings and $29.4B revenue.
4 min read